Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes

Leukemia Research

Volumn 35, Issue 7, 2011, Pages 868-873

  Chu, Sung Chao ^a,b   Wang, Tso Fu ^a   Li, Chi Cheng ^c   Kao, Ruey Ho ^a,b   Li, Dian Kun ^a,b   Su, Yu Chieh ^a,b   Wells, Denise A ^d   Loken, Michael R ^d  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d HEMATOLOGICS INC   (United States)

Author keywords

Diagnosis; Flow cytometry; Myelodysplastic syndromes; Prognosis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AZACITIDINE; CD11B ANTIGEN; CD16 ANTIGEN; CYTARABINE; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE;

ADULT; AGE; AGED; ARTICLE; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CANCER CLASSIFICATION; CANCER SURVIVAL; CELL LINEAGE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FLOW CYTOMETRIC SCORING SYSTEM; FLOW CYTOMETRY; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MONOCYTES; MYELODYSPLASTIC SYNDROMES; MYELOID CELLS; PROGNOSIS; SURVIVAL RATE; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 79958763369     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.02.016     Document Type: Article

References (25)

1. Tefferi A., Vardiman J.W. Myelodysplastic syndromes. New Engl J Med 2009, 361:1872-1885.
2. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Brit J Haematol 1982, 51:189-199.
3. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
4. Valent P., Horny H.P., Bennett J.M., Fonatsch C., Germing U., Greenberg P., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007, 31:727-736.
5. Wells D.A., Benesch M., Loken M.R., Vallejo C., Myerson D., Leisenring W.M., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003, 102:394-403.
6. Ogata K., Nakamura K., Yokose N., Tamura H., Tachibana M., Taniguchi O., et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002, 100:3887-3896.
7. Loken M.R., van de Loosdrecht A., Ogata K., Orfao A., Wells D.A. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res 2008, 32:5-17.
8. Ogata K., Kishikawa Y., Satoh C., Tamura H., Dan K., Hayashi A. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 2006, 108:1037-1044.
9. Elghetany M.T. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2002, 99:391-392.
10. Font P., Subira D., Mtnez-Chamorro C., Castanon S., Arranz E., Ramiro S., et al. Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome. Leuk Res 2006, 30:957-963.
11. Scott B.L., Wells D.A., Loken M.R., Myerson D., Leisenring W.M., Deeg H.J. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 2008, 112:2681-2686.
12. van de Loosdrecht A.A., Westers T.M., Westra A.H., Drager A.M., van der Velden V.H., Ossenkoppele G.J. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008, 111:1067-1077.
13. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
14. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
15. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
16. Li C.C., Loken M.R., Kao R.H., Wang T.F., Tsai H.H., Hsu S.M., et al. Multidimensional flow cytometry for detection of rare populations in hematological malignancies. Tzu Chi Med J 2009, 21:40-51.
17. Stelzer G.T., Shults K.E., Loken M.R. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci 1993, 677:265-280.
18. Westers T.M., Alhan C., Chamuleau M.E., van der Vorst M.J., Eeltink C., Ossenkoppele G.J., et al. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 2010, 115:1779-1784.
19. van de Loosdrecht A.A., Alhan C., Bene M.C., Della Porta M.G., Drager A.M., Feuillard J., et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009, 94:1124-1134.
20. Cutler J.A., Wells D.A., van de Loosdrecht A.A., de Baca M.E., Kalnoski M.H., Zehentner B.K., et al. Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias. Cytometry B Clin Cytom 2010, 23:23.
21. Stachurski D., Smith B.R., Pozdnyakova O., Andersen M., Xiao Z., Raza A., et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 2008, 32:215-224.
22. Matarraz S., Lopez A., Barrena S., Fernandez C., Jensen E., Flores J., et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 2008, 22:1175-1183.
23. Lorand-Metze I., Ribeiro E., Lima C.S., Batista L.S., Metze K. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. Leuk Res 2007, 31:147-155.
24. Truong F., Smith B.R., Stachurski D., Cerny J., Medeiros L.J., Woda B.A., et al. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study. Leuk Res 2009, 33:1039-1046.
25. Ogata K., Della Porta M.G., Malcovati L., Picone C., Yokose N., Matsuda A., et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica 2009, 94:1066-1074.